Aligos Therapeutics, Inc. (ALGS)
Develops experimental drugs to treat liver disease, obesity, and viral infections.
$4.25+0.04%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-43.0%
The outlook
Aligos Therapeutics trades near its 52-week low, well below both its 50- and 200-day moving averages, signaling a weak near-term trend. Analyst consensus is strongly bullish, with an average price target implying substantial upside from current levels. The stock remains thinly valued relative to analyst expectations, though the price action suggests caution.
What’s behind the score
Analyst consensusStrong Buy — 1.1 avg of 7 analysts
Price trendBelow its 50- & 200-day averages
52-week range3% of the way from its 52-week low to high
Price targetAvg target +1224% vs current price
Analyst price target
~12-month · 7 analysts$56.29average target+1224.4% vs now
Now $4.25
Low $20.00High $175.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$26.3M
52-wk high
$13.69
52-wk low
$3.98
50-day avg
$5.52
200-day avg
$7.50
Trailing P/E
—